When is vancomycin prophylaxis necessary? Risk factors for MRSA surgical site infection.


Journal

Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676

Informations de publication

Date de publication:
2024
Historique:
received: 02 10 2023
revised: 16 12 2023
accepted: 20 12 2023
medline: 28 2 2024
pubmed: 28 2 2024
entrez: 28 2 2024
Statut: epublish

Résumé

The 2022 SHEA/IDSA/APIC guidance for surgical site infection (SSI) prevention recommends reserving vancomycin prophylaxis to patients who are methicillin-resistant This was a single-center, case-control study of patients with a postoperative SSI after undergoing a National Healthcare Safety Network operative procedure over eight years. MRSA SSI cases were compared to non-MRSA SSI controls. Forty-two demographic, medical, and surgical characteristics were evaluated. Of the 441 patients included, 23 developed MRSA SSIs (rate = 5.2 per 100 SSIs). In the multivariable model, we identified two independent risk factors for MRSA SSI: a history of MRSA colonization or infection (OR, 9.0 [95% CI, 1.9-29.6]) and hip or knee replacement surgery (OR, 3.8 [95% CI, 1.3-9.9]). Hemodialysis, previous hospitalization, and prolonged hospitalization prior to the procedure had no measurable association with odds of MRSA SSI. Patients with prior MRSA colonization or infection had 9-10 times greater odds of MRSA SSI and patients undergoing hip and knee replacement had 3-4 times greater odds of MRSA SSI. Healthcare-associated characteristics, such as previous hospitalization or hemodialysis, were not associated with MRSA SSI. Our findings support national recommendations to reserve vancomycin prophylaxis for patients who are MRSA colonized, as well as those undergoing hip and knee replacement, in the absence of routine MRSA colonization surveillance.

Sections du résumé

Background UNASSIGNED
The 2022 SHEA/IDSA/APIC guidance for surgical site infection (SSI) prevention recommends reserving vancomycin prophylaxis to patients who are methicillin-resistant
Methods UNASSIGNED
This was a single-center, case-control study of patients with a postoperative SSI after undergoing a National Healthcare Safety Network operative procedure over eight years. MRSA SSI cases were compared to non-MRSA SSI controls. Forty-two demographic, medical, and surgical characteristics were evaluated.
Results UNASSIGNED
Of the 441 patients included, 23 developed MRSA SSIs (rate = 5.2 per 100 SSIs). In the multivariable model, we identified two independent risk factors for MRSA SSI: a history of MRSA colonization or infection (OR, 9.0 [95% CI, 1.9-29.6]) and hip or knee replacement surgery (OR, 3.8 [95% CI, 1.3-9.9]). Hemodialysis, previous hospitalization, and prolonged hospitalization prior to the procedure had no measurable association with odds of MRSA SSI.
Conclusions UNASSIGNED
Patients with prior MRSA colonization or infection had 9-10 times greater odds of MRSA SSI and patients undergoing hip and knee replacement had 3-4 times greater odds of MRSA SSI. Healthcare-associated characteristics, such as previous hospitalization or hemodialysis, were not associated with MRSA SSI. Our findings support national recommendations to reserve vancomycin prophylaxis for patients who are MRSA colonized, as well as those undergoing hip and knee replacement, in the absence of routine MRSA colonization surveillance.

Identifiants

pubmed: 38415081
doi: 10.1017/ash.2024.7
pii: S2732494X2400007X
pmc: PMC10897724
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e10

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

All authors report no conflicts of interest relevant to this article.

Auteurs

Cynthia T Nguyen (CT)

Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.

Rachel Baccile (R)

The Center for Health and the Social Sciences, The University of Chicago, Chicago, IL, USA.

Amanda M Brown (AM)

Department of Infection Prevention and Control, University of Chicago Medicine, Chicago, IL, USA.

Alison K Lew (AK)

Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.

Jennifer Pisano (J)

Department of Medicine, Section of Infectious Diseases and Global Health, Chicago, IL, USA.

Natasha N Pettit (NN)

Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.

Classifications MeSH